Acute-on chronic liver failure  by Jalan, Rajiv et al.
ReviewAcute-on chronic liver failure
Rajiv Jalan1,⇑, Pere Gines2, Jody C Olson3, Rajeshwar P Mookerjee1, Richard Moreau4,
Guadalupe Garcia-Tsao5, Vicente Arroyo2, Patrick S Kamath3
1Liver Failure Group, UCL Institute for Liver and Digestive Health, UCL Medical School, Royal Free Hospital, Rowland Hill Street, London,
United Kingdom; 2Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Catalunya, Spain, Institut d’Investigacions Biomèdiques
August-Pi-Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas yDigestivas (CIBEREHED), Spain; 3Division of
Gastroenterology and Hepatology, Mayo Clinic, College of Medicine, Rochester, MN, United States; 4INSERM, U773, Centre de Recherche
Biomédicale Bichat-Beaujon CRB3, Paris and Clichy, France; 5Section of Digestive Diseases, Yale University School of Medicine,
New Haven, CT, United StatesSummary manifesting as jaundice and coagulopathy, complicated withinAcute-on-chronic liver failure (ACLF) is an increasingly recogni-
sed entity encompassing an acute deterioration of liver function
in patients with cirrhosis, which is usually associated with a
precipitating event and results in the failure of one or more
organs and high short term mortality. Prospective data to deﬁne
this is lacking but there is a large body of circumstantial evidence
suggesting that this condition is a distinct clinical entity. From
the pathophysiologic perspective, altered host response to injury
and infection play important roles in its development. This
review focuses upon the current understanding of this syndrome
from the clinical, prognostic and pathophysiologic perspectives
and indicates potential biomarkers and therapeutic targets for
intervention.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Acute-on-chronic liver failure (ACLF) is an increasingly recognised
entity encompassing an acute deterioration of liver function in
patients with cirrhosis, either secondary to superimposed liver
injury or due to extrahepatic precipitating factors such as infection
culminating in the end-organ dysfunction (Fig. 1). Occasionally, no
speciﬁc precipitating event can be found. Although the exact path-
ophysiology of the development of ACLF remains to be elucidated,
unregulated inﬂammation is thought to be a major contributing
factor. A characteristic feature of ACLF is its rapid progression,
the requirement for multiple organ supports and a high incidence
of short and medium term mortality of 50–90% [1]. The condition
remains undeﬁned but two consensus working deﬁnitions for this
syndrome exist. The ﬁrst was put forward by the Asia–Paciﬁc
association for the study of liver disease [2]; ‘Acute hepatic insultJournal of Hepatology 20
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E-mail address: r.jalan@ucl.ac.uk (R. Jalan).4 weeks by ascites and/or encephalopathy in a patientwith previously
diagnosed or undiagnosed chronic liver disease’; and a second at a
EASL-AASLD single topic symposium [3]; ‘Acute deterioration of
pre-existing, chronic liver disease, usually related to a precipitating
event and associated with increased mortality at 3 months due to
multi-system organ failure’. These deﬁnitions are too imprecise to
allowhomogeneous diagnostic criteria and clinical studies are cur-
rently underway to reach an evidence-based deﬁnition. The latter
deﬁnition implies that organ failure is a central component of this
syndrome and leads to the hypothesis that the organsmay behave
differently to chronic decompensated liver disease. This review
focuses upon the current understanding of this syndrome from
the clinical, prognostic and pathophysiologic perspectives and
indicates potential biomarkers and therapeutic targets for inter-
vention. It is the second deﬁnition that will be used in the descrip-
tion that follows unless otherwise stated.Epidemiology
Data regarding the epidemiology of ACLF is rare. At the recently
held EASL-AASLD Single Topic Symposium on the management
of critically ill cirrhotic patients in the ICU (Atlanta, 2010), data
were presented from the nationwide in-patient sample in the
US for the year 2006. Using the parameters of the need for
mechanical ventilation and/or invasive cardiovascular monitor-
ing, 26,300 patients were identiﬁed. In-hospital mortality was
found to be 53% and the mean length of hospitalization was about
14 days. The total charges associated with the ICU admissions
alone were 3 billion US dollars with a suggestion that the ICU
mortality in cirrhotic patients has remained unchanged [3]. It is
likely that a signiﬁcant proportion of these patients had ACLF
but is difﬁcult to conﬁrm until evidence-based deﬁnition of ACLF
is derived.Clinical and prognostic factors (P)
Data on the natural history of patients with cirrhosis progressing
to multiorgan failure and its outcome are limited. In a study
reported in a preliminary form, the group at UCL hypothesized12 vol. 57 j 1336–1348
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Fig. 1. Acute-on chronic liver failure: diagrammatic representation of the
clinical concept. This ﬁgure describes the clinical concept of ACLF to distinguish
it from chronic decompensated cirrhosis. The red line describes the course of a
patient with chronic decompensation of cirrhosis that during evolution of their
liver disease will at some point develop organ dysfunction. This is usually in
association with advanced liver disease where the only option for treatment is
liver transplantation and the chances of reversibility of liver disease are very
limited. This is in contradistinction to the patient with acute-on chronic liver
failure (depicted by the blue line) who may often have a good liver reserve and
can deteriorate acutely over a short period, usually in association with a
precipitating illness that results in organ failure and high risk of death. The
patient may also have advanced liver disease but be stable and deteriorate
acutely following a precipitating event, and progress to organ failure. By contrast,
this patient has a potential for reversibility and recovery to the state the patient
was in, prior to the acute event.
Table 1. SOFA scoring system.
Organ Measurement Score
PaO2 to FIO2 ratio ≥400 mmHg 0
300 to 399 mmHg 1
200 to 299 mmHg 2
100 to 199 mmHg 3
<100 mmHg 4
Platelet count ≥150,000 per µl 0
100,000 to 149,999 per µl 1
50,000 to 99,999 per µl 2
20,000 to 49,999 per µl 3
<20,000 per µl 4
Serum bilirubin <1.2 mg/dl 0
1.2 to 1.9 mg/dl 1
2.0 to 5.9 mg/dl 2
6.0 to 11.9 mg/dl 3
≥12.0 mg/dl 4
Hypotension MAP ≥70 mmHg 0
MAP <70 mmHg, 
no pressor agents used
1
Dobutamine, any dose 2
Dopamine 5 µg/kg/min 2
Dopamine >5 to 15 µg/kg/min 3
Dopamine >15 µg/kg/min 4
Epinephrine ≤0.1 µg/kg/min 3
Epinephrine >0.1 µg/kg/min 4
Norepinephrine ≤0.1 µg/kg/min 3
Norepinephrine >0.1 µg/kg/min 4
Glasgow coma score 15 0
13-14 1
10-12 2
6-9 3
3-5 4
Serum creatinine or 
urine output
Serum creatinine <1.2 mg/dl 0
Serum creatinine 1.2 to 1.9 mg/dl 1
Serum creatinine 2.0 to 3.4 mg/dl 2
Serum creatinine 3.5 to 4.9 mg/dl 3
Urine output 200 to 499 ml/day 3
Serum creatinine >5.0 mg/dl 4
Urine output <200 ml/day 4
MAP, mean arterial pressure.
JOURNAL OF HEPATOLOGYthat in patients with cirrhosis who present with acute deteriora-
tion of cirrhosis due to a precipitating factor and progress to
develop a single organ dysfunction have signiﬁcantly different
outcome to those that do not develop a single organ dysfunction
[4]. In a prospective study to explore this hypothesis, a group of
patients with liver cirrhosis that were admitted to a single unit
over a 5.5-year period and managed according pre-deﬁned man-
agement guidelines were analyzed. Organ failure was deﬁned as
the need for support of any organ. The patients were followed-up
clinically and biochemically until death or transplantation.
Among the approximately 500 patients studied, about one third
developed a single organ failure, of which 53% died during the
ﬁrst hospital admission, also indicating that the occurrence of a
single organ dysfunction was reversible in nearly 50% of cases.
The study also showed that both the severity of inﬂammation
and the occurrence of new infection were associated with a
higher risk of death [5].
The prognostic factors determining the outcome of patients
with cirrhosis and multiorgan failure are currently under evalua-
tion, but it seems that the scoring systems addressing the sever-
ity of liver disease, such as Child-Pugh score [6] or Model of End
Stage Liver Disease (MELD) [7] perform less well than the scoring
systems addressing organ dysfunction such as the Sequential
Organ Failure Assessment (SOFA) (Table 1) [8] or the Acute Phys-
iology, Age and Chronic Health Evaluation (APACHE) [9] scores.
The available data describing the outcome of patients with cir-
rhosis who develop organ failure and are admitted to the ICU
are summarized in Table 2 and 3 [10–44]. Critical examination
of the data indicates two fundamentally important conclusions.
First, the data suggest that the occurrence of an organ failure in
patients with cirrhosis with a deﬁned severity of liver disease
indicates a poor prognosis with very wide survival ﬁgures, which
is possibly related to criteria for ICU admission. This notion is
supported by the second conclusion that it is not the severity ofJournal of Hepatology 2012liver disease measured using conventional clinical and biochem-
ical testing (Child-Pugh score) that is important, but the degree of
end-organ failure that determines outcome. In these complex
patients, a concept similar to the PIRO concept in sepsis (predis-
position, infection/inﬂammation, response, organ failure) [45] might
be useful in describing pathophysiology and clinical categories
(Fig. 2).vol. 57 j 1336–1348 1337
Table 2. Comparison of the current literature on mortality rates of patients with cirrhosis and organ failure.
Reference Number of patients Patient selection ICU mortality (%) Hospital mortality (%)
Goldfarb et al., 1983 100 Cirrhosis on ICU, MV 89 -
Shellman et al., 1988 100 Cirrhosis on ICU - 64
Zauner et al., 1996 198 Cirrhosis on ICU
Zimmerman et al., 1996 117 Cirrhosis on ICU, MV 63
Lee et al., 1997 47 Cirrhosis on ICU, MV 83 -
Singh et al., 1998 54 Cirrhosis on ICU 43
Kress et al., 2000 138 Cirrhosis on ICU 56
Aggarwal et al., 2001 582 Cirrhosis on ICU 37 49
Wehler et al., 2001 143 Cirrhosis on ICU 36 46
Tsai et al., 2003 111 Cirrhosis on ICU 65
Chen et al., 2003 76 Cirrhosis on ICU, bleeding 68
Chen et al., 2004 67 Cirrhosis on ICU, renal failure 87
Ho et al., 2003 135 Cirrhosis on ICU 67
Tsai et al., 2004 160 Cirrhosis on ICU
Gildea et al., 2004 420 Cirrhosis on ICU 69 (1-yr mortality)
Arabi et al., 2004 129 Cirrhosis on ICU 74 -
Rabe et al., 2004 76 Cirrhosis on ICU, MV 59
du Cheyron et al., 2005 73 Cirrhosis on ICU, renal failure 65, no renal failure 35
Cholongitas et al., 2006 312 Cirrhosis on ICU 65
Mackle et al., 2006 107 Alcoholic liver disease on ICU 58 88
Chen et al., 2006 102 Cirrhosis on ICU 68
Jenq et al., 2007 134 Cirrhosis on ICU 68
Cholongitas et al., 2008 128 Cirrhosis on ICU after 48 h 55
Fang et al., 2008 111 Cirrhosis on ICU, renal failure 82
Juneja et al., 2009 104 Cirrhosis on ICU 42 56
Cholongitas et al., 2009 412 Cirrhosis on ICU 61
Thomson et al., 2010 137 Cirrhosis on ICU 38 47
Filloux et al., 2010 86 Cirrhosis on ICU 37 48
Juneja et al., 2011 73 Cirrhosis on ICU, MV 75 88
Levesque et al., 2012 377 Cirrhosis on ICU 35 43
Cavallazzi et al., 2012 441 Cirrhosis on ICU
Shawcross et al., 2012 660 Cirrhosis on ICU 51
ICU, intensive care unit; MV, mechanical ventilation.
ReviewPathophysiological basis
Precipitating event (I)
ACLF usually results following a precipitating event on the back-
ground of established cirrhosis. The ‘event’ may directly exagger-
ate liver injury such as alcoholic hepatitis, drug-induced liver
injury, superimposed viral hepatitis, portal vein thrombosis and
ischemic hepatitis or liver decompensation may be consequent
upon extra-hepatic insults such as trauma, surgery, variceal
bleeding or infection. In a proportion of patients, there may be
no identiﬁable precipitating event. The best studied precipitating
events are surgery and superimposed viral hepatitis in relation to
the development of ACLF. The most important predictors of
post-operative mortality were severity of liver disease as1338 Journal of Hepatology 2012determined by the MELD score, age, and the American Society
of Anesthesiologists (ASA) score [46]. Patients with a low MELD
score who die immediately following surgery often had cerebral
edema [47].
When HAV infection occurs in the setting of cirrhosis, there is
a substantial risk of ACLF and death [48]. Hepatitis E virus (HEV)
is an important cause of ACLF in Southern and Central Asia, China,
Africa, and the Indian subcontinent and leads to rapid hepatic
decompensation and death. In a prospective study of 107 patients
with cirrhosis of varying severity, mortality was much higher in
patients with superimposed HEV infection vs. non-infected cir-
rhotics. Mortality rate between HEV infected vs. non-infected cir-
rhotics at 4 weeks was 43% vs. 22% (p = 0.001) respectively and
70% vs. 30% (p = 0.001) at one year [49]. Patients who acquire
acute HBV infection in the setting of chronic liver disease arevol. 57 j 1336–1348
Table 3. Comparison of data on prognostic accuracy of organ failure scores and liver disease scores in patients with liver cirrhosis and organ failure.
Reference Number of 
patients
Patient 
selection
APACHE II 
(AUROC)
APACHE III 
(AUROC)
SOFA 
(AUROC)
OFS 
(AUROC)
Child-Pugh 
score (AUROC)
Zauner et al., 1996 198 Cirrhosis on ICU 0.75 0.8 - - -
Zimmerman et al., 1996 117 Cirrhosis on ICU, 
MV
Accurate for 
risk stratification
Singh et al., 1998 54 Cirrhosis on ICU Predicts 
mortality
Does not 
predict mortality
Kress et al., 2000 138 Cirrhosis on ICU Predicts 
mortality
Afessa et al., 2000 111 Cirrhosis on ICU, 
bleeding
0.78 0.76
Wehler et al., 2001 143 Cirrhosis on ICU 0.79 0.94 0.74
Ho et al., 2003 135 Cirrhosis on ICU 0.833 0.75
Tsai et al., 2003 111 Cirrhosis on ICU 0.901 0.748
Chen et al., 2003 76 Cirrhosis on ICU, 
bleeding
0.887 0.900 0.706
Tsai et al., 2004 160 Cirrhosis on ICU 0.892 0.906 0.712
Chen et al., 2004 67 Cirrhosis on ICU, 
renal failure
0.878 0.873
Rabe et al., 2004 76 Cirrhosis on ICU, 
MV
0.66 0.87
Gildea et al., 2004 420 Cirrhosis on ICU Predicts 
mortality
Cholongitas et al., 2006 312 Cirrhosis on ICU 0.78 0.83 0.72
Chen et al., 2006 102 Cirrhosis on ICU 0.91 0.91
Jenq et al., 2007 134 Cirrhosis and 
renal failure on ICU
0.92
Cholangitas et al., 2008 128 Cirrhosis on ICU 
after 48 h
0.78 0.88 0.85 0.78
Fang et al., 2008 111 Cirrhosis on ICU 
with renal failure
Juneja et al., 2009 104 Cirrhosis on ICU 0.90 0.93
Cholangitas et al., 2009 412 Cirrhosis on ICU 0.84
Thomson et al., 2010 137 Cirrhosis on ICU
Filloux et al., 2010 86 Cirrhosis on ICU
Juneja et al., 2011 73 Cirrhosis on ICU 
requiring mechanical 
ventilation
0.77 0.94 0.83
Levesque et al., 2012 377 Cirrhosis on ICU 0.92 0.79
Cavallazzi et al.,
2012
441 Cirrhosis on ICU
ICU, intensive care unit; MV, mechanical ventilation.
JOURNAL OF HEPATOLOGYmore likely to suffer decompensation, which is common in carri-
ers who receive immunosuppressive therapy [50,51]. In a study
from India, patients with reactivation of HBV and ACLF were
shown to have improved survival if they were treated with ten-
ofovir compared with no therapy [52]. Although the ethics of this
study can be questioned, it illustrates that early intervention may
prevent occurrence of multiorgan failure by aggressively target-
ing the precipitating event. This principle is also illustrated by
the demonstration that survival of patients with variceal bleeding
can be improved by the prompt use of antibiotics, which reduces
the risk of infection [53]. Rapid control of the bleeding episode
with the insertion of a transjugular intrahepatic stent shunt in
patients with advanced liver disease or those with activeJournal of Hepatology 2012bleeding saves lives [54,55]. It is likely that the common end
point that leads from the precipitating event to the development
of ACLF is an altered host response to injury, resulting in an
inappropriate inﬂammatory response and immune dysfunction
increasing the susceptibility to infection [56].
Inﬂammation and infection (R)
The role of a systemic inﬂammatory response (SIRS), which is a
collection of simple and relatively crude clinical and hematolog-
ical measure using heart and respiratory rate, white cell count,
and temperature, in determining the outcome of patients with
liver failure was ﬁrst fully described in the acute liver failure,vol. 57 j 1336–1348 1339
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Fig. 2. The PIRO concept of acute-on chronic liver failure. In patients with ACLF, it is useful to think about the PIRO concept in determining pathogenesis and prognosis.
Predisposition is indicated by the severity of the underlying illness. Injury by the nature and severity of the precipitating event. Response by host response to injury, which
determines the severity of inﬂammation and risk of infection. Organs by the extent of organ failure. Categorisation of patients into these entities allows deﬁnition of
interventions and helps deﬁne prognosis at different levels.
Reviewwhere the presence of SIRS was associated with more severe
encephalopathy, associated infection, renal failure, and poor
outcome [57–59]. Elevated levels of multiple pro- and anti-
inﬂammatory cytokines have been described in ACLF including
TNF-a, sTNF-aR1, sTNF-aR2, IL-2, IL-2R, IL-6, IL-8, IL-10, and
IFN-! [60,61]. More recently, the mortality of patients presenting
with renal dysfunction of cirrhosis has been shown to be signiﬁ-
cantly higher in the group with SIRS [62,63]. It is not surprising
that SIRS should be associated with increased inﬂammatory cyto-
kine response but the use of anti-TNF alpha strategies in patients
with alcoholic hepatitis who demonstrate an inﬂammatory
response is associated with an increased risk of infection and
mortality [64,65].
Infection is a common feature of ACLF, which complicates the
natural history and is associated with signiﬁcant morbidity and
mortality [66]. About 40–50% of hospital admissions of cirrhotic
patients are with sepsis and a further 20–40% will develop noso-
comial infections. Overall in-hospital mortality rates of cirrhotic
patients with infection are about 15%, which is about twice those
without infection. The mortality rate of cirrhotic patients with
severe bacterial infection with septic shock is about 60–100%
[66–70]. In cirrhotic patients, sepsis is a common precipitating
event resulting in hepatic encephalopathy, renal dysfunction
and rebleeding, and mortality associated with variceal bleeding.
Vigilance, repeated cultures from various sites, cautious use of1340 Journal of Hepatology 2012in-dwelling cannulas and very early treatment remain the cor-
nerstones of therapy. The relationship between the SIRS response
and infection leads one to hypothesise that an inﬂammatory
response may lead to immune dysregulation, which may predis-
pose to infection that would then further aggravate a pro-inﬂam-
matory response resulting in a vicious cycle [56]. This
immunopathology of ACLF is reminiscent of the multimodal
immunological response observed in patients with severe sepsis,
which is characterised by an initial SIRS response followed by a
mixed (MARS) and subsequently compensated anti-inﬂammatory
response (CARS) (Fig. 3 and 4).
The associated mechanisms of this phenomenon are not clear
but immune paresis has been suggested as a possible mechanism
[71–73]. A recent study in cirrhotic patients suggested that a
genetic predisposition may underlie the risk of infection. The
investigators focussed on Toll-like receptor (TLR) 2 and nucleo-
tide-binding oligomerisation domain (NOD) 2 which recognize
pathogen-associated molecular patterns (PAMS). In a multivari-
ate analysis, they conﬁrmed that TLR2 GT microsatellite polymor-
phism and NOD2 variants were independent predictors of
spontaneous bacterial peritonitis (SBP) when both risk factors
were present, the risk of SBP was dramatically increased (odds
ratio: 11.3; p = 0.00002) [74]. In alcoholic hepatitis patients,
neutrophil activation indicated by increased resting burst and
reduced phagocytic function was predictive of subsequentvol. 57 j 1336–1348
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Fig. 3. Immune dysfunction of acute-on chronic liver failure. This ﬁgure describes the level of immune dysfunction that may be operative in patients with acute-on
chronic liver failure and proposes the hypothesis that the immune status of patients during the illness may not be constant. Patients may move from a pro-inﬂammatory to
an anti-inﬂammatory state, making them susceptible to infection. It is likely that the patients that do not resolve the compensated anti-inﬂammatory response are the ones
that will become infected and have the highest mortality rates.
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Fig. 4. Role of bacterial translocation in acute-on chronic liver failure. In the transition from compensated to decompensated cirrhosis (marked by the development of
variceal hemorrhage, ascites and/or hepatic encephalopathy) increasing portal pressure and liver ﬁbrosis play a predominant role, while vasodilatation (and the resultant
hyperdynamic circulatory state) is not as prominent. Conversely, the development of multiorgan failure is characterized by signiﬁcant alterations in systemic and hepatic
hemodynamics and worsening of liver function. Bacterial translocation plays an important role in the transition of patients from compensated to decompensated cirrhosis,
and together with bacterial infection is the most frequent precipitant of such deterioration via the systemic inﬂammatory response. VH, variceal hemorrhage; HE, hepatic
encephalopathy.
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Review
infection, organ failure and mortality [72]. Importantly, data from
ex vivo studies showed that this neutrophil dysfunction was
reversible and possibly due to a circulating humoral factor that
was hypothesised to be endotoxin [72]. In another study,
monocyte HLA-DR expression was signiﬁcantly reduced in ACLF
who also showed an inability to produce TNF-a, the severity of
which correlated with survival [71–73]. These observations
provide potential biomarkers to predict infection risk and allow
individualisation of therapy. Modulation of enteric microﬂora
with probiotic therapy has been shown to restore neutro-
phil phagocytic capacity [75]. In a randomised clinical trial,
administration of the granulocyte-colony stimulating factor was
associated with improved survival of patients with ACLF [76].
The study included 47 patients with ACLF using the APASL deﬁni-
tion and the investigators showed a very high 2-month mortality
of 71% in the untreated group compared with about 30% in the
treated group. Clearly, this study will need to be repeated with
larger numbers of patients but provides the proof of concept
that modulation of immune paresis may prevent the progression
of ACLF.The organs in ACLF (O)
Liver and hepatic hemodynamics
The hallmark of the liver manifestation of ACLF is hyperbilirubi-
nemia and coagulopathy but the pathophysiological basis is
unclear. It is likely that the histopathological characteristics of
the liver during ACLF will be determined by the underlying cause
of cirrhosis and the nature of the precipitating event. The occur-
rence of ACLF due to a non-speciﬁc insults such as infection or a
variceal bleeding is likely to be different from the effect of direct
hepatotoxins such as drugs or superimposed viral hepatitis.
Recent studies in patients with acute deterioration of alcoholic
cirrhosis and resultant ACLF showed presence of SIRS and biliru-
binostatis as early markers to identify these high-risk patients
[77,78]. The investigators made the important observation that
the presence of bilirubinostasis was associated with an increased
risk of subsequent infection. In another study, in a similar popu-
lation, the role of bilirubinostasis was conﬁrmed and the investi-
gators also observed that K8/18 immunostaining was reduced
suggesting loss of cellular actin and microtubular structure,
which was associated with important prognostic information
[79]. At present, there is no clarity on the mechanism of cell-
death or capacity for regeneration of ACLF livers. Early biopsy
may help in both the management of patients and providing an
understanding of the mechanisms involved, as new drugs, such
as pan-caspase inhibitors or stimulators of hepatic regeneration,
may be useful [80].
Liver inﬂammation is an important determinant of portal
pressure and prognosis in cirrhosis. Patients with ACLF that
occurs on the background of alcoholic hepatitis have increased
plasma TNF-a level and also the highest portal pressures [81].
Indeed anti-TNF-a therapy has been shown to reduce portal
pressure in patients with severe alcoholic hepatitis and cirrhosis
[81]. Several lines of evidence exist implicating gut-derived
endotoxemia in the pathogenesis of portal hypertension [82].
Modulation of the portal bacterial load using antibiotics such
as quinolones and rifaxamin has been associated with a
reduction in inﬂammation and portal pressure [83,84]. Endotoxin1342 Journal of Hepatology 2012neutralisation with high density lipoprotein administration has
been associated with a reduction in portal pressure [85]. An
increase in reactive oxidant species, in particular superoxide, is
also observed in ACLF, contributing to an increase in intrahepatic
resistance by reducing nitric oxide bioavailability [86]. In patients
with ACLF, deﬁned according to APASL criteria, no differences in
the portal hemodynamics between decompensated cirrhosis and
ACLF were observed [87], but using the EASL-AASLD deﬁnition,
the portal pressure was markedly higher [88] in those with ACLF
pointing to the need to carefully deﬁne the population under
study.
Hepatic eNOS activity has been shown to be reduced in the
context of cirrhosis with superadded inﬂammation [89,90]. NOS
activity is subject to regulation by a number of inhibitors such
as asymmetric dimethylarginine (ADMA), which is increased dur-
ing inﬂammation resulting in high ADMA levels [91]. This has
been suggested as both a prognostic marker and a possible target
of therapy. Evidence suggests that in addition to decreased nitric
oxide generation, there is also a reduced response to nitric oxide
in cirrhotic livers likely caused by dysfunction of the cyclic GMP
system. Phosphodiesterase-5 inhibitors such as sildenaﬁl, which
increase cGMP, have been shown to have a beneﬁcial effect on
intrahepatic resistance [92]. Further studies are therefore needed
in ACLF in whom both liver blood ﬂow and intrahepatic resis-
tance are altered.
Kidney dysfunction
HRS is thought to be a functional disorder secondary to circula-
tory dysfunction in which there is splanchnic vasodilatation, a
lowering of arterial blood pressure, intense renal vasoconstric-
tion, impaired cardiac function and marked activation of the sym-
pathetic and neurohormonal systems [93–95]. However, in
patients with ACLF who present with renal dysfunction, the char-
acteristics may be widely variable. Thus, in some patients the cir-
culatory changes may predominate, and in other patients there
may be increased synthesis of pro-inﬂammatory mediators or
both. Administration of terlipressin and albumin remains the cur-
rent gold standard for treatment of patients with HRS, but is
unsuccessful in 54% of patients [96]. It is likely that in these latter
patients different factors predominate in the development of
renal dysfunction. In about 30–40% of patients with cirrhosis
who develop renal dysfunction, a bacterial infection is the precip-
itating cause (SBP) [94]. Indeed, the presence of SIRS in patients
with renal dysfunction was associated with infection in 56% of
the subjects, which was a major independent prognostic factor
for mortality in these patients [63]. Traditionally, renal dysfunc-
tion has been suggested to be reversible with transplantation.
However, recent data suggests that patients that are transplanted
with evidence of renal tubular injury on the background of cir-
rhosis are more likely to require renal replacement therapy after
transplantation than patients undergoing transplantation with
HRS, suggesting that the basis of renal dysfunction in ACLF is
not the same as HRS [97]. The important pathophysiological role
of inﬂammation in modulating renal dysfunction associated with
ACLF is highlighted by the beneﬁt of anti-inﬂammatory agents
such as albumin, pentoxifylline and N-acetylcysteine, which
decreased the risk of renal dysfunction in patients with alcoholic
hepatitis [98,99]. Albumin in this situation probably acts as an
anti-inﬂammatory agent and has been shown to protect the kid-
ney during spontaneous bacterial peritonitis and is associatedvol. 57 j 1336–1348
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Fig. 5. Pathophysiological mechanisms of brain dysfunction in acute-on
chronic liver failure. This ﬁgure describes the possible mechanisms underlying
the pathogenesis of hepatic encephalopathy in acute-on chronic liver failure. It is
likely that similar mechanisms are operative in other organs, where susceptibility
to an inﬂammatory insult is provided by organ characteristics that are a feature of
that particular organ in cirrhosis.
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with improved survival in patients with renal failure [100,101].
Administration of prophylactic norﬂoxacin, a selective gut decon-
taminant reduced the incidence of renal failure and improved
survival [102]. The mechanism of the protective effect of norﬂox-
acin was explored in animal models of cirrhosis and AKI and
shown to result from modulation of renal NFkB and cytokines
possibly mediated through a TLR4-based mechanism. In a preli-
minary observation, increased TLR4 has been shown in renal
tubules in ACLF patients, which was not observed in HRS [103].
These data provide potential novel insights into pathophysiology
and the potential for the development of novel biomarkers and
therapeutic approaches. Thus, the use of urinary biomarkers that
reﬂect renal injury may allow early diagnosis of renal dysfunction
of cirrhosis and allow the functional causes of renal dysfunction
to be better distinguished from the inﬂammatory causes. The bio-
markers of interest are markers of tubular injury such as kidney
injury molecule-1, pi and alpha glutathione S-transferase; mark-
ers of inﬂammation such as NAG, NGAL, FABP, and IL-18 [104]. It
is possible that novel therapeutic approaches may be developed if
this hypothesis can be conﬁrmed.
Brain dysfunction
Hepatic encephalopathy (HE) is a common manifestation of ACLF
[1,105–107]. Local and systemic changes have been implicated in
the pathophysiology of the development of this neurological syn-
drome. From the pathophysiological perspective, like the situa-
tion in acute liver failure, brain swelling is an important feature
of ACLF also [105–108]. As the syndrome occurs on the back-
ground of existing cirrhosis and chronic portacaval shunting, a
degree of brain atrophy protects from this brain swelling, result-
ing in an increase in intracranial pressure. There are, however,
several reports of signiﬁcant increases in intracranial pressure
in patients with ACLF [105–107]. Studies using MRI have shown
that this increase in brain swelling can be reversed with liver
transplantation supporting the notion that, like acute liver fail-
ure, the brain manifestation of ACLF is a reversible disorder
[109]. Ammonia is thought to play a key role in the development
of HE but no direct relationship between the severity of hyperam-
monemia and HE could be demonstrated [110]. On the back-
ground of this hyperammonemia, an added hepatic insult and/
or superimposed inﬂammation leads to the development of brain
edema suggesting a synergy between ammonia and inﬂamma-
tion. The synergy between ammonia and inﬂammation has been
demonstrated in animal models of cirrhosis where acute brain
swelling was observed following administration of endotoxin
mimicking the clinical situation seen in ACLF [108]. The mecha-
nism is likely to be related to generation of cytokines in the brain,
increased iNOS expression, oxidative stress and formation of
nitrated protein adducts [108,111]. Studies in animal models
have suggested that ammonia may prime the brain to the delete-
rious effects of superimposed inﬂammation by induction of
microglial cells, which have a huge repertoire for cytokine pro-
duction; and a reduction in ammonia in cirrhotic models pre-
vents the effect of superimposed inﬂammation [108,111–113].
Conversely, reduction in bacterial translocation using a non-
absorbable antibiotic, rifaximin was shown to prevent the occur-
rence of HE, suggesting that reducing inﬂammation may be pro-
tective as well [114]. Cerebral blood ﬂow is known to be
progressively reduced in cirrhosis but in ACLF may be paradoxi-
cally increased as seen in patients with acute liver failure. In aJournal of Hepatology 2012recent study, the acute effect of insertion of a transjugular intra-
hepatic shunt, which is known to induce endotoxemia, was stud-
ied in patients with cirrhosis. The study demonstrated that TIPSS-
induced endotoxemia led to an increase in the rate of production
of nitric oxide, which was associated with endothelial dysfunc-
tion and increased cerebral blood ﬂow supporting the hypothesis
that multiple hits and brain swelling is a feature of ACLF [115]
(Fig. 5). However, the insertion of TIPSS in relatively well cirrho-
tics without hepatic encephalopathy undergoing TIPSS was not
associated with a change in cerebral blood ﬂow, stressing the
pathophysiologically distinct nature of ACLF from otherwise sta-
ble cirrhosis [116].
Cardiac and systemic hemodynamics
In patients with decompensated cirrhosis, a hyperdynamic cir-
culation is the key hemodynamic feature. The increased cardiac
output observed in this situation is mainly due to a vasodilated
splanchnic bed but paradoxically, the blood ﬂow in other
organ, such as kidneys, brain and peripheral organs, is
decreased [117]. Additionally, patients with cirrhosis may have
an underlying cirrhotic cardiomyopathy, which may make
them susceptible to cardiovascular collapse during an acute
inﬂammatory insult, but data supporting that hypothesis does
not exist [118]. The hallmark of ACLF is cardiovascular collapse
akin to the patients with acute liver failure and severe sepsis,
often requiring large doses of inotropes. Unlike decompensated
cirrhosis, where the cardiac output remains elevated, in ACLF,vol. 57 j 1336–1348 1343
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despite splanchnic vasodilation, the cardiac output can be
reduced and both systolic and diastolic functions are affected.
This cardiovascular abnormality is associated with increased
risk of death, particularly in those patients who present with
renal dysfunction [119]. In another study, where the deﬁnition
of ACLF was based upon the APASL criteria, no differences in
cardiac output were observed, highlighting the fact that the
designation is crucial in deﬁning which patients are being
described. The mechanisms underlying the cardiac dysfunction
in ACLF are likely similar to those in severe sepsis, such as car-
diovascular-active factors like TNF and nitric oxide which are
increased, and cortisol which is decreased [120]. The former
can further dilate the vasculature and the latter decreases the
sensitivity to vasoconstrictors. However, no study has yet dem-
onstrated the beneﬁt of vasodilators/vasoconstrictors in the
management of ACLF. It is important to monitor the cardiac
situation using appropriate methods to guide ﬂuid replacement
and inotrope support. The choice of inotropes is also unclear
but vasopressin analogue in this situation should be used cau-
tiously as it may further reduce cardiac perfusion and an
already compromised hepatic blood ﬂow [121].
Coagulation
Routine diagnostic tests of coagulation are usually abnormal
in patients with cirrhosis due to multiple defects. An
increased bleeding tendency has been attributed to the degree
of abnormalities in these tests, but this has not been formally
proven [122]. Thrombin generation is normal in stable cirrho-
tics with a rebalancing of pro- and anti-coagulant factors (pro-
viding there are sufﬁcient platelets >50,000  109/L). Since
hypercoagulation may exist [123], bleeding abnormalities are
far less frequent than it would be expected [124]. In cirrhosis
with sepsis, endogenous low-molecular weight heparinoids are
detected, and disappear with resolution of infection [68]. Anti-
biotics are known to reduce early variceal rebleeding rates
[125]. The use of prophylactic blood products to correct
abnormalities to prevent bleeding is empirical and often
guided by local protocols; virtually none of these are evi-
dence-based [126]. Moreover, normalization of abnormal coag-
ulation parameters is difﬁcult to achieve, and creates volume
excess, increasing the risk of transfusion-related acute lung
injury and other transfusion reactions. Even recombinant fac-
tor VIIa, which corrects prothrombin time, does not reduce
blood loss during variceal bleeding [127]. Conversely, antiﬁbri-
nolytic agents do reduce blood loss during liver transplanta-
tion, but have not been evaluated prophylactically during
other procedures or for bleeding. Apart from increased ﬁbrino-
lysis, which is seen in ACLF, defective platelet function is the
other major abnormality [128]. The thrombopoietin analog
eltrombopag may be thrombogenic at least in stable cirrhosis
(there has been a suspended trial in this area), probably
because of the interaction with the very high levels of vWF
in cirrhosis. The use of fresh frozen plasma is limited by the
volume of transfusions; safer prothrombin complex concen-
trates which have 20 times the concentration of factors than
FFP are now available [129]. Currently, prophylactic transfu-
sions of any coagulation products are difﬁcult to justify and
it is likely that more comprehensive, global tests of coagula-
tion are needed to guide the correction of coagulation on an
individual basis [130].1344 Journal of Hepatology 2012Hepato-adrenal axis
Adrenal insufﬁciency is reported in 51–68% of patients with
cirrhosis and severe sepsis, particularly in patients with high
Child-Pugh and MELD scores and hemodynamic instability.
Adrenal insufﬁciency is associated with increased mortality
compared to patients without adrenal insufﬁciency [131].
Administration of hydrocortisone to patients with septic shock
and adrenal insufﬁciency was shown to improve the circulatory
function but routine use of hydrocortisone during sepsis has
not been conﬁrmed to improve the outcome [132]. Interpreta-
tion of response to synacthen test in cirrhosis and ACLF is dif-
ﬁcult due to methodological constraints, so no conclusions can
be made.Intensive care management, organ support and
transplantation
Intensive care management of patients with ACLF has been
recently reviewed and a full description is beyond the scope
of this review. The essential principles are those of multiple
organ support to allow the treatment of the precipitating
event and the recovery of the liver. The two speciﬁc aspects
of treatment relevant to this group of patients are discussed
below [3].
Liver support devices are intended to provide detoxiﬁcation
functions to patients with ACLF until liver transplantation, recov-
ery or futility. The overall efﬁcacy of liver support devices have
failed to reach a level sufﬁcient to gain approval for widespread
use [133]. Liver support devices are of two main types; artiﬁcial
livers-acellular devices such as albumin dialysis and plasma-
exchange/diaﬁltration, and bio-artiﬁcial livers, which incorporate
cells from human, animal, or transformed sources. An unpub-
lished study using the ELAD device which incorporates liver can-
cer cells, C3A cells, into the device, was shown in a preliminary
study to be useful in patients with ACLF, mainly induced by
HBV reactivation in a small randomised controlled study [134].
A pivotal clinical trial in USA and Europe has been stopped. None
of the bioartiﬁcial liver devices as far as we know, are in clinical
trials for ACLF patients at present.
The best studied artiﬁcial liver support devices are the
molecular adsorbents recirculating system (MARS) and Prome-
theus devices, which are based upon the principles of albumin
dialysis [135]. These devices are based on the concept that albu-
min is a complex molecule with a plethora of physiological
functions besides providing oncotic properties [136]. Studies
have demonstrated that during hepatic failure, the circulating
albumin undergoes structural and functional modiﬁcations that
negatively affect its biological activity [136]. These devices are
designed to provide additional detoxiﬁcation functions. Several
studies have conﬁrmed that the use of these devices can remove
inﬂammatory molecules, reduce NO and improve systemic and
hepatic hemodynamics, severe hepatic encephalopathy leading
to large clinical trials [61]. The randomised controlled trial of
the Prometheus device in patients with ACLF has been recently
published [137]. The data show that the approach is safe and
well tolerated, although there is no overall signiﬁcant survival
beneﬁt at 28 days. Subgroup analysis suggested that patients
with a MELD score of >30 and those with hepatorenal syndrome
may have some beneﬁt. MARS was tested in a similar cohort,vol. 57 j 1336–1348
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the RELIEF trial, which has been reported in a preliminary com-
munication and again failed to show any survival beneﬁt [138].
A better deﬁnition of ACLF would allow the study of a more
homogenous cohort, but it is likely that modiﬁcations to the
current devices will be necessary to improve their efﬁcacy and
capacity.
Liver transplantation in patients with ACLF has not been sys-
tematically analysed but a recent retrospective study was per-
formed in 332 patients of whom 157 patients had ACLF and
175 patients had no ACLF pre-transplant [139]. Thirty-four
patients received a liver-kidney transplant, of whom 10
(29.4%) had ACLF. The deﬁnition was based on a rapid increase
in MELD by >5 points. The results showed that the group with
ACLF had a 26% mortality compared with a mortality of 17% in
the non-ACLF group. The difference was statistically different in
univariate analysis, but when only single organ transplants
were analysed, the results were not statistically different. On
multivariate analysis, ACLF was not an independent predictor
of post-transplant mortality, arguing strongly that this is a
good indication for transplantation [139]. The timing of trans-
plantation is crucial as patients with ACLF may provide a win-
dow of opportunity. Therefore, living-donor transplantation is
an attractive option, the experience of which has been reported
extensively from South-East Asia, mainly in patients with ACLF
resulting from re-activation of hepatitis B virus infection. The
data from Hong Kong suggests that although the patients with
ACLF and HRS had stormier post-operative course, living donor
transplantation could be performed safely and overall there
were no signiﬁcant differences in survival with 5-year survivals
of about 80% [140]. Similar observations have been made
regarding the safety and feasibility of living donor transplanta-
tion from the Chinese groups [141]. Currently, in most coun-
tries there is no priority for ACLF patients who have
signiﬁcantly higher short-term mortality. A better understand-
ing of the natural history and prognostic criteria will allow
ACLF to be incorporated as a possible new indication for high
urgency allocation.Conclusions and future perspectives
In conclusion, ACLF is a devastating syndrome with inordinately
high mortality, which is clinically, pathophysiologically and
prognostically a distinct clinical entity, but the condition has
not yet been deﬁned. In order to ﬁll this knowledge gap, groups
in Europe, US and Asia have started to study this entity as part
of large consortia. One such consortium in Europe, the EASL
CLIF-Consortium, has just ﬁnished the recruitment of 1400
patients prospectively; the results of the study are eagerly
awaited [142]. It is likely that a better deﬁnition will require
new biomarkers, which will allow the development of new
drugs and devices and, therefore, engagement with the industry
will be crucial to bring these emerging treatments to patients.
The liver transplant community will need to be engaged to
deﬁne which patients with ACLF should be transplanted and
deﬁne new allocation policy. Finally, it is likely that there will
be a resurgence of research activity in cirrhosis to allow the
determination of modiﬁable factors that predispose to ACLF,
and likely to personalise their management based on clinical
and genetic factors.Journal of Hepatology 2012Key Points 
• Acute-on chronic liver failure is a syndrome that defines 
a subgroup of cirrhotic patients who develop organ 
failure following hospital admission with or without an 
identifiable precipitating event and have increased 
mortality rates
• Altered host response to injury such as deranged 
systemic inflammatory response plays an important 
pathophysiological role
• Bacterial infection that occurs on the background of 
varying degrees of immune paralysis plays an important 
role in determining the outcome of this syndrome
• Systemic, cardiac and hepatic hemodynamics are 
important determinants of outcome
• The end-organs such as the kidney and the brain show 
evidence of inflammation
• Survival of patients is dependent upon the severity of 
organ failure
• Treatment strategies are limited to organ support but 
better understanding of the pathophysiology is likely to 
lead to discovery of novel biomarkers and therapeutic 
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